Tennis Player Novak Djokovic Holds Majority Stake In European Biotech Working On COVID-19 Treatment

Serbian professional tennis player Novak Djokovic reportedly has a controlling shareholder in a Danish biotech firm aiming to develop a treatment for COVID-19 that does not involve vaccination.

  • According to Reuters, Novak Djokovic bought an 80% stake in Denmark-based QuantBioRes in 2020.
  • Djokovic was deported from Australia after the government canceled his visa in a dispute over a medical exemption relating to his unvaccinated status.
  • Related: A Novak Djokovic Timeline: A Funny Thing Happened On The Way To The Australian Open.
  • Ivan Loncarevic, QuantBioRes's CEO, confirmed the investment to Reuters but declined to say how much it was.
  • QuantBioRes has about a dozen researchers working in Denmark, Australia, and Slovenia, according to Loncarevic, who stressed that the company was working on a treatment, not a vaccine. 
  • The company's website says it started developing a "deactivation mechanism" for COVID-19 in July 2020.
  • Djokovic and his wife Jelena own 40.8% and 39.2% in QuantBioRes, respectively, the report noted, citing the Danish company register.
  • Djokovic is currently ranked as world No. 1, and Forbes listed him in the world's top-50 highest-paid athletes for 2021. 
  • It calculated his on-court earnings at $4.5 million, compared to $30 million he earned off the court.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSportsGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!